Treating Melasma — A Multi-Modal Approach

Last updated: 5 March 2026

Melasma represents one of the most challenging pigmentary disorders in dermatology, characterised by symmetrical brown to grey-brown patches typically on the face. Its complex, multifactorial aetiology and frustrating tendency to recur despite treatment require comprehensive, multi-modal therapeutic approaches combining sun protection, topical agents, procedural interventions, and patient education.

Understanding Melasma: Aetiology and Classification

Melasma results from increased melanin production by hyperactive melanocytes, triggered by multiple factors including ultraviolet and visible light exposure, hormonal influences (pregnancy, oral contraceptives, hormone replacement therapy), genetic predisposition (more common in darker skin types—Fitzpatrick III-VI), and heat exposure (occupational or environmental).

Clinical Classification:

Melasma is classified by distribution pattern (centrofacial—most common, affecting forehead, cheeks, nose, upper lip; malar—cheeks and nose; and mandibular—jawline) and depth of pigmentation assessed via Wood’s lamp examination (epidermal—darkens under Wood’s lamp, responds better to treatment; dermal—no enhancement under Wood’s lamp, more treatment-resistant; and mixed—combination of both, requires layered treatment approach).

Understanding pigment depth guides treatment selection—epidermal melasma responds to topical therapies and superficial procedures, whilst dermal pigmentation requires deeper interventions or acceptance of slower, partial improvement.

The Foundation: Rigorous Photoprotection

Sun protection isn’t optional in melasma management—it’s the absolute foundation upon which all treatments build. Even brief, incidental UV exposure can trigger melanocyte reactivation and pigment darkening within hours.

Comprehensive Photoprotection Strategy:

Broad-Spectrum SPF 50+ with Iron Oxides: Standard sunscreens block UVB and UVA but allow visible light penetration. Research in JAMA Dermatology demonstrates that visible light (particularly blue light 400-500nm) stimulates melanogenesis in melasma-prone skin. Tinted sunscreens containing iron oxides scatter visible light, providing superior melasma protection compared to non-tinted formulations. Apply 1/4 teaspoon to face; reapply every 2 hours during sun exposure.

Physical Barriers: Wide-brimmed hats (minimum 7.5cm brim), UV-protective sunglasses, and seeking shade during peak UV hours (10am-4pm) complement sunscreen. For occupational or lifestyle sun exposure, consider UV-protective clothing (UPF 50+).

Antioxidant Enhancement: Topical antioxidants including vitamin C, vitamin E, and ferulic acid neutralise free radicals generated by UV exposure, providing synergistic photoprotection when applied beneath sunscreen.

Visible Light and Heat Avoidance: Computer screens, smartphone displays, and indoor lighting emit blue light that may trigger melanogenesis. Some patients benefit from blue light-filtering screen protectors. Avoid heat exposure including hot yoga, saunas, and occupational heat, which can exacerbate melasma independent of UV exposure.

First-Line Topical Therapies

Triple Combination Cream (Hydroquinone + Tretinoin + Corticosteroid):

The modified Kligman formula combining 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide represents the most evidence-based topical melasma treatment. The synergistic mechanism includes hydroquinone inhibiting tyrosinase (the enzyme necessary for melanin synthesis), tretinoin accelerating cell turnover to expedite pigment removal and enhance hydroquinone penetration, and corticosteroid reducing inflammation from hydroquinone and tretinoin whilst providing independent melanocyte-suppressing effects.

Clinical trials demonstrate 60-80% improvement after 8-12 weeks of nightly application. Treatment protocols typically involve 8-12 weeks continuous use followed by maintenance regimen (2-3 nights weekly) or transition to non-hydroquinone alternatives to prevent ochronosis (paradoxical darkening from prolonged hydroquinone use).

Alternative Topical Agents:

Tranexamic Acid: This antifibrinolytic agent reduces melanin synthesis through multiple pathways including plasmin inhibition (which activates melanocytes), VEGF reduction (decreasing blood vessel formation that supports melanocytes), and direct tyrosinase inhibition. Topical tranexamic acid 2-5% demonstrates efficacy comparable to 4% hydroquinone without associated risks. Safe for long-term use.

Azelaic Acid: This naturally occurring dicarboxylic acid inhibits tyrosinase whilst normalising keratinisation and providing anti-inflammatory benefits. Available in 15-20% prescription formulations and 10% over-the-counter products. Particularly beneficial for melasma with concurrent acne or rosacea. Generally well-tolerated for long-term maintenance.

Kojic Acid: Derived from fungi, kojic acid inhibits tyrosinase and provides antioxidant benefits. Concentrations of 1-4% are used in combination products. Some formulations can cause irritation or allergic contact dermatitis; patch testing is advisable.

Vitamin C (L-Ascorbic Acid): High-concentration vitamin C (10-20%) at pH 3.5 or lower inhibits melanin synthesis whilst providing antioxidant photoprotection. Enhances efficacy of other brightening agents. Formulation stability is crucial—airless pumps and opaque packaging prevent oxidation.

Cysteamine: This naturally occurring aminothiol demonstrates promising results in clinical trials with efficacy approaching hydroquinone. Applied as a cream for specified contact time then washed off. Generally well-tolerated but has unpleasant odour limiting acceptability for some patients.

Procedural Interventions: Advanced Treatment Options

Chemical Peels:

Superficial and medium-depth peels accelerate pigment removal whilst stimulating cellular renewal. Glycolic acid (20-70%), salicylic acid (20-30%), and modified Jessner’s solution are commonly used. Melasma-specific considerations include epidermal melasma responds better than dermal or mixed, darker skin types (Fitzpatrick IV-VI) require conservative approach to prevent post-inflammatory hyperpigmentation (PIH), and pre-treatment with topical brightening agents for 4-6 weeks optimises results and reduces PIH risk.

Treatment protocols involve series of 4-6 peels spaced 2-4 weeks apart. Combination Jessner’s peel with 10-20% TCA shows excellent results but requires experienced practitioner and aggressive photoprotection post-procedure.

Laser and Light-Based Treatments:

Laser therapy for melasma is controversial—whilst some patients achieve excellent results, others experience worsening (laser-induced PIH). Current evidence supports cautious, conservative use with specific protocols.

Low-Fluence Q-Switched Nd:YAG Laser (LFQSY): Sub-therapeutic fluences (1-2 J/cm²) at 1064nm wavelength show promise for melasma with lower PIH risk than traditional settings. Mechanism likely involves selective targeting of melanosomes without significant thermal damage. Requires series of 6-10+ treatments spaced 1-2 weeks apart. Best suited to Fitzpatrick III-IV; higher-risk in types V-VI.

Fractional Lasers (Non-Ablative): 1550nm fractional erbium glass lasers create microscopic treatment zones that expedite pigment removal whilst stimulating collagen. Conservative settings with extended treatment intervals (4-6 weeks) minimise PIH risk. Requires thorough informed consent regarding PIH possibility.

Intense Pulsed Light (IPL): Broad-spectrum light targets melanin for gradual lightening. Safer in experienced hands for Fitzpatrick I-III; generally contraindicated in types V-VI due to high PIH risk. Conservative settings with aggressive pre- and post-treatment photoprotection essential.

Tranexamic Acid Injections and Oral Therapy:

Intradermal Injections: Microinjections of tranexamic acid (4mg/ml solution) directly into melasma patches provide localised high concentrations without systemic exposure. Protocols involve 4-8 sessions spaced 2-4 weeks apart. Emerging evidence shows promising results with excellent safety profile.

Oral Tranexamic Acid: Systemic therapy at 250-500mg daily demonstrates effectiveness in numerous studies, with 50-80% improvement after 2-6 months. Mechanism likely involves reduced melanocyte activation through plasminogen inhibition and decreased VEGF. Contraindications include history of thromboembolism, bleeding disorders, stroke, and cardiovascular disease. Requires medical supervision and informed consent regarding off-label use and theoretical thrombotic risk (though not demonstrated in clinical trials at aesthetic doses).

Combination Treatment Protocols: The Multi-Modal Advantage

Optimal melasma management combines multiple modalities targeting different pathways.

Sample Comprehensive Protocol:

Months 1-3 (Foundation Phase): Daily broad-spectrum SPF 50+ tinted sunscreen, strict visible light and heat avoidance, nightly triple combination cream or alternative topical therapy, and morning vitamin C serum beneath sunscreen.

Months 3-6 (Intensive Phase): Continue strict photoprotection and topical therapy, add series of 4-6 chemical peels (glycolic or modified Jessner’s) spaced 3-4 weeks, consider oral or intradermal tranexamic acid if appropriate and no contraindications, and consider low-fluence laser if topicals and peels show insufficient improvement (with careful patient selection and informed consent).

Months 6+ (Maintenance Phase): Lifelong rigorous photoprotection (non-negotiable), maintenance topical therapy 2-3 nights weekly (azelaic acid, tranexamic acid, or vitamin C to avoid prolonged hydroquinone), periodic maintenance peels (every 2-3 months), and prompt intervention for any recurrence.

Managing Expectations: The Melasma Reality

Honest expectation-setting prevents frustration and treatment abandonment. Melasma is chronic and prone to relapse—even excellent initial improvement can be followed by recurrence with sun exposure, hormonal changes, or heat. Complete clearance is uncommon; 50-80% improvement is considered excellent. Treatment requires months (minimum 3-6) before significant improvement is apparent. Lifelong photoprotection is mandatory, not optional. Some dermal pigment may be treatment-resistant. PIH from aggressive treatment can worsen appearance temporarily.

Understanding these realities allows patients to appreciate improvements achieved and maintain treatment adherence.

Special Populations and Considerations

Pregnancy and Breastfeeding: Many melasma treatments are contraindicated during pregnancy and lactation including hydroquinone (controversial safety data, generally avoided), tretinoin and retinoids (teratogenic), chemical peels (generally avoided due to systemic absorption concerns), and oral tranexamic acid (insufficient safety data). Safe options include rigorous photoprotection, vitamin C and azelaic acid, and some gentle peels under dermatologist supervision.

Darker Skin Types (Fitzpatrick V-VI): Require modified approaches with higher PIH risk necessitating conservative treatment, longer pre-treatment preparation with topical brightening, extended intervals between procedural treatments, and possibly accepting more gradual improvement to minimise complications.

Key Takeaways

• Melasma requires multi-modal treatment combining photoprotection, topicals, and procedures
• Tinted SPF 50+ with iron oxides provides superior protection by blocking visible light
• Triple combination cream remains first-line topical therapy with best evidence
• Chemical peels and low-fluence lasers can enhance results when used conservatively
• Lifelong photoprotection is essential to maintain improvements and prevent recurrence

Medical Disclaimer: This article provides educational information only and does not constitute medical advice. Melasma treatment should be supervised by qualified dermatologists who can assess pigment depth, skin type, contraindications, and create personalised treatment protocols. Off-label medication use (oral tranexamic acid) requires informed consent and medical supervision. Laser treatments carry significant PIH risk and should only be performed by experienced practitioners following thorough consultation. Individual results vary significantly, and complete clearance cannot be guaranteed. Pregnant and breastfeeding patients require special consideration regarding safe treatment options.